Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib
Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study
Biomea Fusion Shares Fall After Pricing Underwritten Public Offering